Specific risk factors contributing to early and late recurrences of intrahepatic cholangiocarcinoma after curative resection

Table 4 Univariate analysis of factors related to late recurrence

Variate	HR	95% CI	P value
Gender
Male vs. female	1.206	0.745–1.954	0.445
Age (year)	1.000	0.981–1.020	0.986
ALT (U/L)	1.144	0.602–2.172	0.682
AST (U/L)	1.365	0.794–2.347	0.258
ALP (U/L)	1.336	0.785–2.273	0.205
γ-GT (U/L)	1.219	0.771–1.929	0.397
TBIL (μmol/L)	1.485	0.862–2.556	0.154
HBV infection
Positive vs. negative	0.587	0.298–1.157	0.124
HBV-DNA load (IU/mL)
≥ 10³ vs. < 10³	1.145	0.703–1.865	0.587
HBV-DNA load (IU/mL)
≥ 10⁶ vs. < 10⁶	1.784	1.023–3.111	0.038
Cirrhosis
Yes vs. no	0.910	0.567–1.461	0.698
Child-Pugh class
B vs. A	1.283	0.468–3.516	0.625
Hepatolithiasis history
Yes vs. no	2.661	1.265–5.599	0.007
AFP (ng/mL)
> vs. ≤ 20	0.781	0.429–1.422	0.416
CEA (μg/L)
> 10 vs. ≤ 10	3.555	1.107–11.412	0.022
CA19–9 (U/L)
> 37 vs. ≤ 37	1.331	0.836–2.117	0.228
Tumor size (cm)
> vs. ≤ 5	1.383	0.875–2.183	0.163
Tumor number
Multiple vs. single	1.661	0.719–3.836	0.235
Satellite
Yes vs. no	1.308	0.689–2.484	0.411
Macrovascular invasion
Yes vs. no	1.176	0.288–4.800	0.819
Microvascular invasion
Yes vs. no	1.544	0.214–11.143	0.663
Capsule integrity
Yes vs. no	0.881	0.322–2.415	0.806
E-S grade
III vs. I or II	0.895	0.174–4.616	0.311
LNM
Yes vs. no	1.355	0.546–3.362	0.509
TNM stage
III vs. I or II	1.483	0.680–3.232	0.317

Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase, γ-GT γ-glutamyl transpeptidase, TBIL total bilirubin, HBV-DNA hepatitis B virus deoxyribonucleic acid, AFP alpha-fetoprotein, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, E-S Edmondson-Steiner, LNM lymph node metastasis. There were statistically significant differences for data in Italics (p < 0.05)

ISSN: 1477-7819